267 online
 
Most Popular Choices
Share on Facebook 39 Printer Friendly Page More Sharing Summarizing
Diary   

Medical Whistleblower interviews Eli Lilly Insider Dr. John Virapen


Janet Parker
Message Janet Parker

Medical Whistleblower will be interviewing Former Eli Lilly executive, Dr. John Virapen Ph.D. on Monday July 27, 2009 at 9 AM Central Time on BlogTalkRadio. Dr. John Virapen has been working for more than 30 years for the pharmaceutical industry, as manager for Eli-Lilly and Novo Nordisk. He lives now in Germany and has written about his experiences in the pharmaceutical industry in a block buster book, Side Effects: Death, which is available in English, Swedish and German. This information is very especially important in the wake of the recent $1.4 billion settlement from drug maker, Eli Lilly. The drug giant, Eli Lilly, recently plead guilty to promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA). Eli Lilly was found guilty of pushing Zyprexa for extra label uses, withholding research to the public and false advertising. The criminal fine of $515 million is the largest ever in a health care case, and the largest criminal fine for an individual corporation ever imposed in a United States criminal prosecution of any kind. Eli Lilly will also pay up to $800 million in a civil settlement with the federal government and the states.

There have been years of withheld information regarding the adverse side effects of pharmaceuticals promoted by Eli Lilly, including the possible role of Prozac in inducing suicide and homicide. The signs of drug induced violence and suicidality were there since Prozac was first tested in premarketing trials. There were reports of Prozac's adverse side effects of psychotic episodes; reports of completed suicides and attempted suicides, seizures, and even movement disorders.

Oraflex, the American version of Benoxaprofen, was withdrawn from the market in 1982, just one month after gaining FDA approval. A British medical journal found five cases of death due to jaundice in patients taking the drug and the FDA accused Eli Lilly of suppressing unfavorable research findings.

The health risks of Zyprexa included an increased risk for diabetes through Zyprexa's links to obesity and its tendency to raise blood sugar. Zyprexa is Lilly's top-selling drug, with sales of $4.2 billion and over 20 million people worldwide who have taken Zyprexa. Eli Lilly is accused of aggressively marketing Zyprexa and other drugs for extra-label uses by primary care physicians. Long term effects of the use of SSRI's like Zyprexa have not been fully independently studied but these drugs are routinely prescribed for long term use. Preliminary studies point to serious potential adverse side effects of chronic use including movement disorders, cardiac problems, diabetes and Parkinson's disease.

Join us for the radio show on Monday July 27 at 9 AM Central Time (10 AM Eastern Time or 7 AM Pacific Time) call (34.... click on the Medical Whistleblower show on the internet and listen through your computer at www.blogtalkradio.com/medicalwhistleblower.

See Dr. John Virapen on YouTube: http://www.youtube.com/watch?v=s-8ItXRMPfA

Read about his story on the web at: click here

Must Read 2   Well Said 2   Valuable 2  
Rate It | View Ratings

Janet Parker Social Media Pages: Facebook page url on login Profile not filled in       Twitter page url on login Profile not filled in       Linkedin page url on login Profile not filled in       Instagram page url on login Profile not filled in

Medical Whistleblower is an organization dedicated to advocacy and emotional support for those who have bravely stepped forward to "Tell Truth to Power" to the Medical Establishment. Medical Whistleblowers report Medical Fraud, Abuse and (more...)
 

Go To Commenting
The views expressed herein are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.
Writers Guidelines

 
Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
Support OpEdNews

OpEdNews depends upon can't survive without your help.

If you value this article and the work of OpEdNews, please either Donate or Purchase a premium membership.

STAY IN THE KNOW
If you've enjoyed this, sign up for our daily or weekly newsletter to get lots of great progressive content.
Daily Weekly     OpEd News Newsletter
Name
Email
   (Opens new browser window)
 

To View Comments or Join the Conversation:

Tell A Friend